The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Travellight and all
Forgive me I've missed some messages on this BB that have covered this question already but, isn't it possible for Avacta to find a way of making the LFT work such that the whole functionality is governed by Affimers or, at least reagents that are under Avacta control? If not, why not? (If it is possible, it begs the question why haven't they done it already? Maybe that points to it not being possible? [if you assume Aacta are wholly switched on and competent])
Phantom, i think you're right. This seems to be a perilous underlying issue for Avacta - was there sufficient honesty in the earlier technical presentations?
~Now that we know the LFT is dependent on an antibody component, do we know who provides this? Is it is under Avacta's control or, are we going into another 12 month process of dependency on a contracted relationship?
How big a problem is it? Avacts's RNS doesn't say anything about whether finding a replacement antibody component is easy, difficult, under there control or dependent on another party.
As seems to happen too often an Avacta RNS raises more questions that it answers?
Hope you're right HappyDays, but fear you are trumpeting just another false dawn that you're trumpeting. Until it actually happens it seems Avacta is now firmly in the "disappoints" box -as the SP level and trend seems to show.
We need to see AVACTA confirm the Avacta LFT picks up Omicron but, has Avacta even got hold of an omicron sample to test its LFT against yet? Based on past record, such an Avacta assessment and announcement may be months away, if it comes at all? I hope they can do it soon - next week - but, I'm not going to hold my breath for it.
Seems like "no news is good news" is an optimistic view of the below? Cant be straight forward, otherwise would have been public by now? Or, have I missed something? I know the wheels of such legal administration turn very slowly but.....FOUR months since saying the work was done......!3rd August RNS - FOUR months ago said:- Further to the Company's announcement of 2 July 2021 in which Rockhopper reported that the Tribunal had informed the Company that it expected to complete its work in July, the Company can confirm it has yet to receive news of the outcome of the process.
Forget ramping and deramping.
The company needs to produce and sell a material quantity of its masks, the the SP will rise because more shares will be bought than sold.
The New Variant provides a opportunity for Avacta to shake off its hopeless performance over its LFT to date:-
Get the Avacta LFT tested against the new variant; prove it still works or, quickly develop a version that does work.
Do this urgently and convincingly and, maybe the tide of sentiment will turn back in Avacta's favour.
And, who know, Avacta might actually start selling some LFTs.
Ref from the June RNS below.
H2 CY 2021 - that means about 7 weeks left. Will the FDA approval come through? If it does will the SP rise? (Or is it priced in already?)
"In line with industry best practice ANGLE does not intend to provide any further updates on communication with FDA regarding the submission whilst the regulatory process is as expected. ANGLE continues to anticipate a regulatory decision from FDA during H2 CY 2021*.
Well, we are now well into autumn 2021. and still no material sales of the LFT.
When Avacta failed to get its LFT product out on sale in 2020 despite the CEO's hype that there would be sales then, I was trolled by the CEO worshippers on this BB. When I said said , perhaps the CEO always meant it was to be in 2021, some seemed to agree - yes, the CEO never really said sales would happen in 2020.
So, here we are again. Maybe CEO Smith really meant there might be material sales by autumn 2022?
What odds on that , still no better than 50:50 , even now?
Why am I posting this? Well, to bring some reality to this BB. I'd hate to think others might read some CEO worship here and invest their money without some non-CEO worship being visible.
(Though it 's noticeable there's not as much CEO worship as there used to be on here. It seems his spell has worn off, even for the previous truest believers)
I'm invested. I originally invested for the cancer treatment and am holding for the chance that comes good. I've made some profit on the LFT hype but, then, stupidly, invested more at higher SP and am now holding large loss relative to purchase price.
Here's hoping the cancer treatment does come good but, the reality of the CEO and Avacta's performance in LFT marketing and true manufacturing, distribution and sales contracting is that the cancer treatment success-hope is definitely just that - a hope.
Good luck Avacta holders and buyers.
I'm really struggling with how positive spin about Avacta can be put on this Abingdon tweet.
To me it just raises the questions - where the hec is Avacta's LFT production line? How has Avacta failed so badly to make use of Abingdon's capacity?
Mikey279,
I'm sure you're aware but, just in case anyone reading might assume otherwise - if you wait until AS announces shelving of the LFT before you sell, you could well be selling at less than 50p a share. (Unless you think the LFT is already effectively written off within the existing 110 - 120 p SP?).